Comparison of Pittsburgh compound B and florbetapir in crossâ sectional and longitudinal studies
dc.contributor.author | Su, Yi | |
dc.contributor.author | Flores, Shaney | |
dc.contributor.author | Wang, Guoqiao | |
dc.contributor.author | Hornbeck, Russ C. | |
dc.contributor.author | Speidel, Benjamin | |
dc.contributor.author | Joseph‐mathurin, Nelly | |
dc.contributor.author | Vlassenko, Andrei G. | |
dc.contributor.author | Gordon, Brian A. | |
dc.contributor.author | Koeppe, Robert A. | |
dc.contributor.author | Klunk, William E. | |
dc.contributor.author | Jack, Clifford R. | |
dc.contributor.author | Farlow, Martin R. | |
dc.contributor.author | Salloway, Stephen | |
dc.contributor.author | Snider, Barbara J. | |
dc.contributor.author | Berman, Sarah B. | |
dc.contributor.author | Roberson, Erik D. | |
dc.contributor.author | Brosch, Jared | |
dc.contributor.author | Jimenez‐velazques, Ivonne | |
dc.contributor.author | Dyck, Christopher H. | |
dc.contributor.author | Galasko, Douglas | |
dc.contributor.author | Yuan, Shauna H. | |
dc.contributor.author | Jayadev, Suman | |
dc.contributor.author | Honig, Lawrence S. | |
dc.contributor.author | Gauthier, Serge | |
dc.contributor.author | Hsiung, Ging‐yuek R. | |
dc.contributor.author | Masellis, Mario | |
dc.contributor.author | Brooks, William S. | |
dc.contributor.author | Fulham, Michael | |
dc.contributor.author | Clarnette, Roger | |
dc.contributor.author | Masters, Colin L. | |
dc.contributor.author | Wallon, David | |
dc.contributor.author | Hannequin, Didier | |
dc.contributor.author | Dubois, Bruno | |
dc.contributor.author | Pariente, Jeremie | |
dc.contributor.author | Sanchez‐valle, Raquel | |
dc.contributor.author | Mummery, Catherine | |
dc.contributor.author | Ringman, John M. | |
dc.contributor.author | Bottlaender, Michel | |
dc.contributor.author | Klein, Gregory | |
dc.contributor.author | Milosavljevic‐ristic, Smiljana | |
dc.contributor.author | McDade, Eric | |
dc.contributor.author | Xiong, Chengjie | |
dc.contributor.author | Morris, John C. | |
dc.contributor.author | Bateman, Randall J. | |
dc.contributor.author | Benzinger, Tammie L.S. | |
dc.date.accessioned | 2020-01-13T15:16:26Z | |
dc.date.available | WITHHELD_12_MONTHS | |
dc.date.available | 2020-01-13T15:16:26Z | |
dc.date.issued | 2019-12 | |
dc.identifier.citation | Su, Yi; Flores, Shaney; Wang, Guoqiao; Hornbeck, Russ C.; Speidel, Benjamin; Joseph‐mathurin, Nelly ; Vlassenko, Andrei G.; Gordon, Brian A.; Koeppe, Robert A.; Klunk, William E.; Jack, Clifford R.; Farlow, Martin R.; Salloway, Stephen; Snider, Barbara J.; Berman, Sarah B.; Roberson, Erik D.; Brosch, Jared; Jimenez‐velazques, Ivonne ; Dyck, Christopher H.; Galasko, Douglas; Yuan, Shauna H.; Jayadev, Suman; Honig, Lawrence S.; Gauthier, Serge; Hsiung, Ging‐yuek R. ; Masellis, Mario; Brooks, William S.; Fulham, Michael; Clarnette, Roger; Masters, Colin L.; Wallon, David; Hannequin, Didier; Dubois, Bruno; Pariente, Jeremie; Sanchez‐valle, Raquel ; Mummery, Catherine; Ringman, John M.; Bottlaender, Michel; Klein, Gregory; Milosavljevic‐ristic, Smiljana ; McDade, Eric; Xiong, Chengjie; Morris, John C.; Bateman, Randall J.; Benzinger, Tammie L.S. (2019). "Comparison of Pittsburgh compound B and florbetapir in crossâ sectional and longitudinal studies." Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11(C): 180-190. | |
dc.identifier.issn | 2352-8729 | |
dc.identifier.issn | 2352-8729 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/153056 | |
dc.description.abstract | IntroductionQuantitative in vivo measurement of brain amyloid burden is important for both research and clinical purposes. However, the existence of multiple imaging tracers presents challenges to the interpretation of such measurements. This study presents a direct comparison of Pittsburgh compound Bâ based and florbetapirâ based amyloid imaging in the same participants from two independent cohorts using a crossover design.MethodsPittsburgh compound B and florbetapir amyloid PET imaging data from three different cohorts were analyzed using previously established pipelines to obtain global amyloid burden measurements. These measurements were converted to the Centiloid scale to allow fair comparison between the two tracers. The mean and interâ individual variability of the two tracers were compared using multivariate linear models both crossâ sectionally and longitudinally.ResultsGlobal amyloid burden measured using the two tracers were strongly correlated in both cohorts. However, higher variability was observed when florbetapir was used as the imaging tracer. The variability may be partially caused by white matter signal as partial volume correction reduces the variability and improves the correlations between the two tracers. Amyloid burden measured using both tracers was found to be in association with clinical and psychometric measurements. Longitudinal comparison of the two tracers was also performed in similar but separate cohorts whose baseline amyloid load was considered elevated (i.e., amyloid positive). No significant difference was detected in the average annualized rate of change measurements made with these two tracers.DiscussionAlthough the amyloid burden measurements were quite similar using these two tracers as expected, difference was observable even after conversion into the Centiloid scale. Further investigation is warranted to identify optimal strategies to harmonize amyloid imaging data acquired using different tracers. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | Positron emission tomography | |
dc.subject.other | Centiloid | |
dc.subject.other | PiB | |
dc.subject.other | Florbetapir | |
dc.subject.other | Amyloid imaging | |
dc.title | Comparison of Pittsburgh compound B and florbetapir in crossâ sectional and longitudinal studies | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Neurology and Neurosciences | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/153056/1/dad2jdadm201812008.pdf | |
dc.identifier.doi | 10.1016/j.dadm.2018.12.008 | |
dc.identifier.source | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring | |
dc.identifier.citedreference | C.C. Rowe, U. Ackerman, W. Browne, R. Mulligan, K.L. Pike, G. O’Keefe, et al. Imaging of amyloid beta in Alzheimer’s disease with 18Fâ BAY94â 9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7: 2008; 129 â 135 | |
dc.identifier.citedreference | D.M. Holtzman, J.C. Morris, A.M. Goate. Alzheimer’s Disease: The Challenge of the Second Century. Sci Transl Med. 3: 2011; 77 sr1 | |
dc.identifier.citedreference | A. Leuzy, K. Chiotis, S.G. Hasselbalch, J.O. Rinne, A. de Mendonca, M. Otto, et al. Pittsburgh compound B imaging and cerebrospinal fluid amyloidâ beta in a multicentre European memory clinic study. Brain. 139: 2016; 2540 â 2553 | |
dc.identifier.citedreference | D.F. Wong, P.B. Rosenberg, Y. Zhou, A. Kumar, V. Raymont, H.T. Ravert, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18Fâ AVâ 45 (florbetapir [corrected] F 18). J Nucl Med. 51: 2010; 913 â 920 | |
dc.identifier.citedreference | W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, D.P. Holt, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compoundâ B. Ann Neurol. 55: 2004; 306 â 319 | |
dc.identifier.citedreference | V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, O. Salvado, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 12: 2013; 357 â 367 | |
dc.identifier.citedreference | W.J. Jansen, R. Ossenkoppele, D.L. Knol, B.M. Tijms, P. Scheltens, F.R. Verhey, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a metaâ analysis. JAMA. 313: 2015; 1924 â 1938 | |
dc.identifier.citedreference | T.L. Benzinger, T. Blazey, C.R. Jack Jr., R.A. Koeppe, Y. Su, C. Xiong, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci U S A. 110: 2013; E4502 â E4509 | |
dc.identifier.citedreference | J.C. Morris, A.L. Price. Pathologic correlates of nondemented aging, mild cognitive impairment, and earlyâ stage Alzheimer’s disease. J Mol Neurosci. 17: 2001; 101 â 118 | |
dc.identifier.citedreference | C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9: 2010; 119 â 128 | |
dc.identifier.citedreference | R.J. Bateman, C. Xiong, T.L. Benzinger, A.M. Fagan, A. Goate, N.C. Fox, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 367: 2012; 795 â 804 | |
dc.identifier.citedreference | R. La Joie, N. Ayakta, W.W. Seeley, E. Borys, A.L. Boxer, C. DeCarli, et al. Multisite study of the relationships between antemortem [(11)C]PIBâ PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 15: 2019; 205 â 216 | |
dc.identifier.citedreference | V.J. Lowe, E.S. Lundt, M.L. Senjem, C.G. Schwarz, H.K. Min, S.A. Przybelski, et al. White matter reference region in PET studies of (11)Câ Pittsburgh compound B uptake: Effects of age and Amyloidâ beta deposition. J Nucl Med. 59: 2018; 1583 â 1589 | |
dc.identifier.citedreference | M. Veronese, B. Bodini, D. Garciaâ Lorenzo, M. Battaglini, S. Bongarzone, C. Comtat, et al. Quantification of [(11)C]PIB PET for imaging myelin in the human brain: a testâ retest reproducibility study in highâ resolution research tomography. J Cereb Blood Flow Metab. 35: 2015; 1771 â 1782 | |
dc.identifier.citedreference | B. Bodini, M. Veronese, F. Turkheimer, B. Stankoff. Benzothiazole and stilbene derivatives as promising positron emission tomography myelin radiotracers for multiple sclerosis. Ann Neurol. 80: 2016; 166 â 167 | |
dc.identifier.citedreference | S.M. Landau, A. Fero, S.L. Baker, R. Koeppe, M. Mintun, K. Chen, et al. Measurement of Longitudinal betaâ Amyloid Change with 18Fâ Florbetapir PET and Standardized Uptake Value Ratios. J Nucl Med. 56: 2015; 567 â 574 | |
dc.identifier.citedreference | K. Chen, A. Roontiva, P. Thiyyagura, W. Lee, X. Liu, N. Ayutyanont, et al. Improved power for characterizing longitudinal amyloidâ beta PET changes and evaluating amyloidâ modifying treatments with a cerebral white matter reference region. J Nucl Med. 56: 2015; 560 â 566 | |
dc.identifier.citedreference | S.M. Landau, C. Breault, A.D. Joshi, M. Pontecorvo, C.A. Mathis, W.J. Jagust, et al. Amyloidâ beta Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods. J Nucl Med. 54: 2013; 70 â 77 | |
dc.identifier.citedreference | C. Xiong, M.S. Jasielec, H. Weng, A.M. Fagan, T.L. Benzinger, D. Head, et al. Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Neurology. 86: 2016; 1499 â 1506 | |
dc.identifier.citedreference | C.R. Jack Jr., H.J. Wiste, S.D. Weigand, T.M. Therneau, V.J. Lowe, D.S. Knopman, et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement. 13: 2017; 205 â 216 | |
dc.identifier.citedreference | Y. Su, S. Flores, R.C. Hornbeck, B. Speidel, A.G. Vlassenko, B.A. Gordon, et al. Utilizing the Centiloid scale in crossâ sectional and longitudinal PiB PET studies. NeuroImage: Clin. 19: 2018; 406 â 416 | |
dc.identifier.citedreference | B.A. Gordon, T.M. Blazey, Y. Su, A. Hariâ Raj, A. Dincer, S. Flores, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer’s disease: a longitudinal study. Lancet Neurol. 17: 2018; 241 â 250 | |
dc.identifier.citedreference | O.G. Rousset, D.L. Collins, A. Rahmim, D.F. Wong. Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J Nucl Med. 49: 2008; 1097 â 1106 | |
dc.identifier.citedreference | A. Joshi, R.A. Koeppe, J.A. Fessler. Reducing between scanner differences in multiâ center PET studies. Neuroimage. 46: 2009; 154 â 159 | |
dc.identifier.citedreference | Y. Su, G.M. D’Angelo, A.G. Vlassenko, G. Zhou, A.Z. Snyder, D.S. Marcus, et al. Quantitative analysis of PiBâ PET with FreeSurfer ROIs. PLoS One. 8: 2013; e73377 | |
dc.identifier.citedreference | Y. Su, T.M. Blazey, A.Z. Snyder, M.E. Raichle, D.S. Marcus, B.M. Ances, et al. Partial volume correction in quantitative amyloid imaging. Neuroimage. 107: 2015; 55 â 64 | |
dc.identifier.citedreference | P. Pastor, C.M. Roe, A. Villegas, G. Bedoya, S. Chakraverty, G. Garcia, et al. Apolipoprotein Eepsilon4 modifies Alzheimer’s disease onset in an E280A PS1 kindred. Ann Neurol. 54: 2003; 163 â 169 | |
dc.identifier.citedreference | M.F. Folstein, S.E. Folstein, P.R. McHugh. â Miniâ mental stateâ . A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12: 1975; 189 â 198 | |
dc.identifier.citedreference | C.L. Sutphen, M.S. Jasielec, A.R. Shah, E.M. Macy, C. Xiong, A.G. Vlassenko, et al. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol. 72: 2015; 1029 â 1042 | |
dc.identifier.citedreference | A.G. Vlassenko, L. McCue, M.S. Jasielec, Y. Su, B.A. Gordon, C. Xiong, et al. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Ann Neurol. 80: 2016; 379 â 387 | |
dc.identifier.citedreference | J.C. Morris. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 43: 1993; 2412 â 2414 | |
dc.identifier.citedreference | S.M. Mills, J. Mallmann, A.M. Santacruz, A. Fuqua, M. Carril, P.S. Aisen, et al. Preclinical trials in autosomal dominant AD: implementation of the DIANâ TU trial. Rev Neurol. 169: 2013; 737 â 743 | |
dc.identifier.citedreference | M. Navitsky, A.D. Joshi, I. Kennedy, W.E. Klunk, C.C. Rowe, D.F. Wong, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 14: 2018; 1565 â 1571 | |
dc.identifier.citedreference | C.C. Rowe, V. Dore, G. Jones, D. Baxendale, R.S. Mulligan, S. Bullich, et al. (18)Fâ Florbetaben PET betaâ amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 44: 2017; 2053 â 2059 | |
dc.identifier.citedreference | C.C. Rowe, G. Jones, V. Dore, S. Pejoska, L. Margison, R.S. Mulligan, et al. Standardized Expression of 18Fâ NAV4694 and 11Câ PiB betaâ Amyloid PET Results with the Centiloid Scale. J Nucl Med. 57: 2016; 1233 â 1237 | |
dc.identifier.citedreference | W.E. Klunk, R.A. Koeppe, J.C. Price, T.L. Benzinger, M.D. Devous Sr., et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 11: 2015; 1 â 15, e1â e4 | |
dc.identifier.citedreference | Z. Cselenyi, M.E. Jonhagen, A. Forsberg, C. Halldin, P. Julin, M. Schou, et al. Clinical validation of 18Fâ AZD4694, an amyloidâ betaâ specific PET radioligand. J Nucl Med. 53: 2012; 415 â 424 | |
dc.identifier.citedreference | R. Vandenberghe, K. Van Laere, A. Ivanoiu, E. Salmon, C. Bastin, E. Triau, et al. 18Fâ flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 68: 2010; 319 â 329 | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.